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Abstract
Introduction: AP-2a is a transcription factor implicated in the regulation of differentiation and proliferation in
certain tissues, including the mammary gland. In breast tumours, continued expression of AP-2a has been
correlated with a better prognosis, but this is hard to reconcile with a reported role in the upregulation of the
ERBB2 oncogene. The existence of TFAP2A isoforms, deriving from alternative first exons and differing in their N-
terminal sequence, has been described in some mammals, but their relative abundance and activity has not been
investigated in the human breast.
Methods: Expression levels of four TFAP2A isoforms were assayed at the level of RNA and protein (via the
generation of isoform-specific antibodies) in a panel of breast tumour cell lines and in tissue from normal breast
and primary tumour samples. Expression constructs for each isoform were used in reporter assays with synthetic
and natural promoters (cyclin D3 and ERBB2) to compare the activation and repression activity of the isoforms.
Results: We demonstrate that the two isoforms AP-2a 1b and AP-2a 1c, in addition to the originally cloned, AP-
2a 1a, are conserved throughout evolution in vertebrates. Moreover, we show that isoform 1c in particular is
expressed at levels at least on a par with the 1a isoform in breast epithelial lines and tissues and may be more
highly expressed in tamoxifen resistant tumours. The isoforms share a similar transactivation mechanism involving
the recruitment of the adaptors CITED2 or 4 and the transactivators p300 or CBP. However, isoform 1b and 1c are
stronger transactivators of the ERBB2 promoter than isoform 1a. In contrast, AP-2a 1a is the only isoform able to
act as a repressor, an activity that requires an intact sumoylation motif present within the N-terminus of the
protein, and which the other two isoforms lack.
Conclusions: Our findings suggest that TFAP2A isoforms may be differentially regulated during breast
tumourigenesis and this, coupled with differences in their transcriptional activity, may impact on tumour responses
to tamoxifen therapy. These data also have implications for the interpretation of tumour studies that seek to
correlate outcomes with TFAP2A expression level.
Introduction
AP-2a belongs to the AP-2 family of transcription fac-
tors with four other members, AP-2b, g, δ and ε [1],
which have all been implicated in the regulation of pro-
liferation and differentiation in specific tissues. In parti-
cular, AP-2a is expressed in the developing and adult
mammary gland [2,3]. In breast cancer, lower AP-2a
expression levels are found in invasive cancer compared
to ductal carcinoma in situ (DCIS) and normal breast
[4], while high levels of AP-2a correlate with a more
favourable outcome [2,5]. Among the known target
genes, many play a key role in breast biology and
tumorigenesis. AP-2a is a central player in the positive
regulation of ERBB2 expression [6], supported by studies
demonstrating a correlation between AP-2a levels and
expression of the receptor in tumour samples [5,7], but
in conflict with other observations [4]. How the role of
AP-2a as a tumour suppressor reconciles with its activ-
ity in inducing ERBB2 is still unclear.
AP-2 proteins interact as homo- and hetero-dimers
which bind to specific GC-rich sequences to regulate
transactivation or repression [8]. The best characterised
mechanism of transactivation involves the recruitment
of the transcriptional activators CBP and p300 through
interaction with the small adaptor proteins CITED2 [9]
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vivo is underlined by the observation that CITED2 and
AP-2a knockout mice have overlapping phenotypes
[11]. AP-2a is known to repress expression of a number
of genes, including C/EBPa [12], Bcl-2 [13], EGFR [14],
but the mechanism of repression is unknown. However,
the related AP-2g is known to interact with UBC9 and
to be sumoylated, resulting in downregulation of its
transcriptional activity [15].
The TFAP2A gene consists of seven exons with the
last six exons encoding the majority of the protein,
including the activation, DNA binding and dimerisation
domains [1]. The existence of different TFAP2A iso-
forms deriving from alternative first exons has been
described in murine embryo and HeLa cells [16], and in
ovine and human placenta [17]. Some variation in spa-
tio-temporal expression between the isoforms during
murine embryonic development was identified using in
situ hybridisation [16]; however, the function of these
splice variants, which differ solely in the extreme amino-
terminal sequence of AP-2a, has not been investigated
further. Generally, transcripts deriving from alternative
first exons are frequently observed in mammalian gen-
omes, with an estimated >20% of genes having active
alternative promoters [18]. This contributes to the com-
plexity of the function of a gene by providing additional
levels of regulation of expression and, if the translation
s t a r ts i t ee x i s t sw i t h i nt h ef i r s te x o na si nt h ec a s eo f
AP-2a, by encoding distinct proteins which potentially
have quite different biological functions.
Our aim was to characterise the role of human AP-2a
isoforms in normal breast epithelial cells and tumours,
addressing their expression levels and comparing their
transcriptional activities.
Materials and methods
Additional sequences used to analyse TFAP2A isoform
conservation
Xenopus tropicalis (1a: NM_001037258.1, 1b: BC135698,
1c: CR848274.2); Danio rerio (1a: NM_176859.2, 1b:
BC066582, 1c: AF457192.1).
Antibodies and plasmids
AP-2a isoform-specific antibodies were generated utilis-
ing the peptides representing the different isoforms (1a:
KLTDNIKYEDCEDRHDGTSN, 1b: LVHSFSAMDRH
DC, 1c: SILAKMGDWQDRC 1d: GGARGQTGPGSAC),
coupled to the KLH carrier protein, injected in rabbits
according to standard protocols. The specificity of the
antibodies was tested in Western blot on extracts of
HepG2 overexpressing the different isoforms. Isoform 4
serum was specific and was further used in a dilution
1:100. Other isoform-specific antibodies were further
purified utilising the peptides KLTDNIKYEDCEDRC
(1a), LVHSFSAMDRC (1b), and SILAKMGDWQDRC
(1c) coupled to a SulfoLink Coupling Gel Column
(Thermo Fisher Scientific Inc, Rockford, IL, USA)),
according to the manufacturer’s instructions, eluted with
the corresponding peptides, and concentrated. The iso-
form 1a antibody was further incubated on a SulfoLink
column conjugated to the peptide
(DRHDGTSNGTARLC) to retain exon 2 binding anti-
bodies. Pan-AP-2a (3B5), actin and HSC70 antibodies
were from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA). pcDNA3 encoding full length human AP-2a
isoform 1a [19] was mutagenised to the WT sequence
(V2L) using the GeneEditor kit (Promega UK, South-
ampton, UK). Expression plasmids for isoforms 1b, 1c
and 1d were generated in the same background. The N-
terminal portion of the cDNA encoding AP-2a isoform
1c was generated by PCR with the primers GATGTC-
CATACTTGCCAAAATGG and TGAGGTA-
CATTTTGTCCATGGC from cDNA generated from
MCF10A cells and sublcloned by KpnI-BlpI digestion
into pcDNA3 AP-2a, thus substituting the 5’ sequence
of isoform 1a. pcDNA3 AP-2a isoform 1b was gener-
ated by substituting the HindIII-BlpI fragment of
pcDNA3-AP-2a-1a with the EarI-BlpI fragment of
IMAGE clone 4432023. pcDNA3 AP-2a isoform 1d was
generated by substituting the fragment HindIII-BlpI of
pcDNA3-AP-2a-1a with the SfoI-BlpI fragment from
IMAGE clone OE37H07. All constructs were verified by
sequencing. Isoform 1a was further mutagenised (K10R)
using the QuickChange kit (Agilent Technologies UK
Ltd, Wokingham, UK). Other plasmids were: pCI-p300
[20], pRc/CMV CBP [21], pcDNA3-CITED2 [11],
p c D N A 3 - C I T E D 4[ 1 0 ] ,p S G 5s u m o 1ΔHSTV and pSG5
sumo2 ΔV Yg e n e r a t e db yP C R ,p S G 5u b c 9[ 1 5 ] ,p S G 5
Ubc9 C93S [15]. Reporter plasmids were: 3xAP2-Bluc
[11], p500LUC, generated by subcloning the -500/+40
ERBB2 promoter fragment from p500CAT [22] into
pGL3-basic (Promega), and cyclin D3 generated by clon-
ing the region (-201,+162) into pGL3 basic. For normali-
sation, reporters expressing Renilla luciferase (pGL4.74
hRluc/TK or phRG-TK; Promega) were utilised.
Cell culture, transfection and cell extracts
All cell lines were from the ATCC and were cultivated
according to the criteria provided: HepG2 cells -
DMEM supplemented with 10% foetal calf serum, peni-
cillin and streptomycin; MCF10A - DMEM:F12 1:1 sup-
plemented with EGF, hydrocortisone, cholera toxin,
insulin, 5% horse serum, penicillin and streptomycin
[23]. Tamoxifen-resistant cell lines were cultivated in
10
-7 M tamoxifen for six months. Cells were transiently
transfected with GeneJuice (Merck KGaA, Darmstadt,
Germany) in a 24-well format for luciferase experiments
(80,000 cells/well) or 6-well format for Western blot
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Genejuice. The total amount of DNA transfected was
normalised using the appropriate empty vectors. Cells
were harvested after 48 h, lysed and assayed using the
dual luciferase reporter system (Promega). Firefly luci-
ferase readings were normalised to renilla luciferase
values. All transfection experiments were performed in
triplicate and repeated at least three times; the average,
with the SE, is shown. Statistical analysis was performed
utilising Student’s t-test. Extracts for Western blot were
generated utilising RIPA buffer (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1%
SDS, 1% Nonidet P-40). Where indicated, isopeptidase
inhibitors were included at 10 mM iodoacetamide (IAA)
and 20 mM N-ethylmaleimide (NEM). Alternatively, cell
pellets were resuspended directly in urea buffer (8 M
urea, 1 M thiourea, 0.5% CHAPS, 50 mM DTT, 24 mM
spermine). Western blot quantifications were achieved
using ImageJ software [24], using a t-test for statistical
analysis.
RNA preparation and RT-PCR
RNA was extracted using the RNAeasy kit (Qiagen UK,
Crawley, UK). We used 1 μg of total RNA to reverse
transcribe with Superscript III (Life Technologies Cor-
poration, Carlsbad, CA, USA). Real-time PCR of the dif-
ferent isoforms was performed using SybrGreen (Life
Technologies) according to standard cycling protocols
with 300 nM of specific forward primer (isoform 1a:
ATATCAAGTACGAGGACTGCG, isoform 1b:
AGATGTTAGTTCACAGTTTTTCAGC, isoform 1c:
GATGTCCATACTTGCCAAAATGG, isoform 1d:
CCAAGCAGCTCCTACC), and 50 nM of common
reverse primer TTGCGACTGGGGGTAGATAG. Abso-
lute amounts of each isoform were determined by gen-
erating a standard curve from a known amount of each
linearised pcDNA3-AP-2a plasmid.
Tumour samples
Fresh frozen tissue from 11 ER + ve patients was
obtained from Guys and St Thomas/King’s College Lon-
don (GSTFT/KCL) Breast Tissue Bank (Ethics approval
number LREC Ref 06/Q0603/25). All were treated with
tamoxifen after surgery; tamoxifen resistant patients had
relapsed within two years. Normal breast tissue samples
were provided by Prof. Louise Jones (LREC Ref 05Q403/
199). Statistical analysis was performed using the Mann-
Whitney test.
Results
TFAP2A alternative first exons are conserved in
vertebrates
The human TFAP2A gene structure and expressed
sequence tags (ESTs) were analysed and the existence of
three isoforms, assigned as reference sequences named
isoform 1a, 1b, and 1c, was confirmed (Figure 1a, b). In
addition, the existence of a fourth isoform, whose
exon is located between exons 1a and 1b was suggested
(Figure 1a). AP-2a isoform 1a corresponds to the AP-
2a cDNA originally cloned [19] and is represented by
nine ESTs. AP-2a isoforms 1b and 1c are represented
respectively by 10 and 8 ESTs. The fourth splice variant,
which we named isoform 1d, is represented by three
ESTs, only one of which, derived from a corneal cDNA
library, is correctly spliced.
Alternative transcripts are not always functional, but a
criterion that suggests biological activity is conservation
across species. Our analysis revealed that highly con-
served homologs of AP-2a 1a and 1b are found in
mammals and in Xenopus tropicalis and Danio rerio.
AP-2a 1c is also well conserved in mammals, and has a
homolog in X. tropicalis and D. rerio, although with a
lower sequence conservation (Figure 1c). This conserva-
tion of the isoforms across species suggests they have
b e e nu n d e rp o s i t i v es e l e c t i v ep r e s s u r ea n dh e n c eh a v e
distinct roles required for normal development. The one
exception may be 1d since the sequence and structure
of this exon is conserved only in primates; therefore,
given that this isoform is represented by only one cor-
rectly spliced EST, its existence is more questionable.
All the alternative first exons identified encode for at
least one possible initiator methionine. Exon 1a, 1b and
1c each encode for a very short sequence of amino
acids, resulting in proteins with a very similar predicted
molecular weight, while exon 1d encodes for a longer
N-terminus (60 residues) (Figure 1b). All the reported
isoforms - with the exception of 1d - have two in-frame
alternative methionine residues (Figure 1b). For isoform
1a, the starting methionine was determined to be the
downstream one by amino-terminal peptide sequencing
when the protein was originally purified [19]. For iso-
forms 1b and 1c, since both methionine residues are
conserved across different species, we searched for a
Kozak sequence to help predict the relative strength of
each translation initiation site [25]. This suggested that
for isoform 1b, the downstream ATG may encode the
predominant starting methionine residue. However, we
could not differentiate between the two ATGs in iso-
form 1c since both have a conserved purine at position
-3.
TFAP2A isoforms 1a and 1c are expressed at a similar
level in breast cell lines and tissue
In order to examine the relative expression of the differ-
ent isoforms in breast tissue, a specific real time PCR
assay was set up to discriminate between each of the
amino-terminal variants. This analysis revealed that iso-
form 1a is the predominant isoform at the RNA level in
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normal breast tissue (Figure 2a). A significant, albeit
lower, expression of isoforms 1b and 1c was also
detected in the cell lines and the tissue samples (Figure
2a). In contrast, isoform 1d levels were very low, sug-
gesting that this isoform, if it exists, does not play a pro-
minent role in the breast. 1d expression was investigated
additionally in an RNA sample from human foetal eye
where, again, the mRNA levels were undetectable (not
shown).
To investigate expression at the protein level, isoform
specific antibodies were generated (as described in
Materials and methods). An antibody affinity analysis
was performed by transfecting HepG2 cells, which do
not express detectable levels of AP-2a,w i t hs p e c i f i c
expression plasmids generated for each isoform, under
the control of the CMV promoter. The expression levels
of the different isoforms, as assessed using an antibody
against the common DNA binding domain of the
protein (pan-AP-2a, 3B5), were consistently similar (Fig-
ure 2b). The same quantity of each lysate was used as a
loading control for subsequent isoform-specific Western
blots (Figure 2b). AP-2a 1a and 1c antibodies bound to
their respective isoform with high affinity, while the 1b-
specific antibody showed significantly lower affinity
(compare Figures 2b and 2c). Western blot analysis of a
panel of breast tumour lines showed that isoform 1a
was expressed at modest levels in all the cell lines inves-
tigated (Figure 2c). A faint band corresponding to the
molecular weight of isoform 1b could be detected in all
t h ec e l ll i n e s ,b u tt h el o wa f f i n i t yo ft h ea n t i b o d ym a d e
it difficult to reliably distinguish it above the back-
ground (Figure 2c). In contrast, isoform 1c was
expressed at significant levels in all the cell lines investi-
gated, with the exception of Cal51, which also lacked
detectable expression at the mRNA level (Figure 2a, c).
Isoform 1d protein was not detected in any of the cell
lines (not shown), in accordance with the mRNA data.
1a                                            MKMLWKLTDNIKYEDCE DRHDGT
1b                                                    MLVHSFSAM DRHDGT
1c                                                  MSILAKMGDWQ DRHDGT
1d MEEPRSSGQPSPESQTRLRSGGARGQTGPGSACRAESPTSARTRSQAAPTRYARPPLHPE DRHDGT
                                                        exon 1        exon 2
3 2 1b 1d 1a 1c
≈1kb
≈0.25kb
≈2kb ≈4kb
a
b
D. rerio       MSLMGKMGDWQ 11
H. sapiens     MSILAKMGDWQ 11
X. tropicalis  MALLAKMGEWQ 11
               *:::.***:** 
TFAP2B        MLVHTYSSM 9
TFAP2E        MLVHTYSAM 9
TFAP2A        MLVHSFSAM 9
              ****::*:*
TFAP2D  MSTTFPGLVH--DAE 13
               ***  .: 
cd
Figure 1 TFAP2A gene contains four alternative first exons which encode conserved protein sequences. (a) Schematic representation of
TFAP2A 5’ gene structure (exons 1 to 3). Exons are shown as rectangles, introns as horizontal lines, drawn in proportion to their actual length.
Closed rectangles represent translated regions, open rectangles represent untranslated regions. Isoforms 1b and 1c are orthologous to the
murine isoform 3 [16] and ovine variant 6 [17], respectively. (b) TFAP2A protein sequences encoded by the four alternative first exons. Possible
starting methionine residues are underlined. AP-2a isoform/variant 4 (as described in [16] and [17], respectively), generated by initiation of
transcription upstream of exon 2, does not have a human paralog due to the presence of an in-frame stop codon upstream of exon 2. (c)
Alignment of TFAP2A isoform 1c protein sequences in H. sapiens, D. rerio and X. tropicalis generated by ClustalW. Sequences for rhesus, mouse,
dog and elephant are identical to the human sequence. * indicates an identical amino acid; : and . indicate conserved and semi-conserved
substitutions, respectively. A conserved TATA-box is present 237 bp upsteam of the ATG. (d) Alignment of TFAP2A isoform 1b protein sequence
to TFAP2B isoform 1b (EST: BM727695), TFAP2D (NM_172238.3) and TFAP2E (NM_178548.3) generated by ClustalW. Human sequences are shown.
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Figure 2 AP-2a isoforms 1a, 1b, and 1c are expressed in breast cell lines and tissues. (a) cDNA was generated from the indicated breast
cell lines (left) and normal breast samples (right) and the relative amount of the different AP-2a isoforms was determined by real-time PCR as
described in the Materials and methods. (b) HepG2 cells were transfected with pcDNA3 expression vectors encoding each isoform and
harvested after 48 h. Two different amounts of cell lysate (5 and 2.5 μg) were loaded for each isoform. Western blot analysis was performed with
a pan-AP-2a antibody, 3B5, which recognises an epitope in the DNA-binding domain of the protein common to all isoforms. (c) Protein lysates
(30 μg) derived from the indicated cell lines were analysed by western blot with isoform-specific antibodies. As a loading control, two amounts
of lysate from HepG2 cells overexpressing each isoform from (b) were loaded on each gel and the blots were also reprobed for actin (lower
panels).
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line and transfected HepG2 control lysates, suggested
that protein levels of isoform 1c are at least comparable
to those of isoform 1a in many lines. This was examined
graphically, by scanning the Western blots (see Figure
S1 in Additional File 1), which demonstrated that iso-
form 1c is expressed at significantly higher levels in the
majority of lines examined,i n c l u d i n gM C F 1 0 A ,T 4 7 D ,
ZR75-1, MDA-MB 361 and MDA-MB 468 cells. There-
fore, the protein levels of isoforms 1a and 1c are much
more similar than would be inferred from the mRNA
data alone and this disproportion between mRNA and
protein levels suggests that these two isoforms are dif-
ferentially regulated either at the translational or post-
translational level.
TFAP2A isoforms share a similar transactivation
mechanism
We next explored whether the isoforms have distinct
biological properties. The DNA binding activity of the
isoforms was compared using electromobility shift assays
(EMSA) and nuclear extracts from HepG2 cells trans-
fected for each of the different isoforms. This revealed
that they all have a similar affinity for a consensus AP-2
DNA binding site (Figure S2 in Additional File 1). All
the isoforms showed a high stability, without detectable
differences in half-life when exogenously expressed in
HepG2 cells (not shown).
To determine whether all the isoforms can act as
transactivators in combination with CITED2 or 4 and
CBP or p300, their activity was analysed in HepG2 cells
cotransfected with a synthetic AP-2 dependent luciferase
reporter construct widely used to characterise AP-2
activity [11]. Most expression constructs for the 1a
isoform carry a mutation at the second amino acid
(V2L), introduced when AP-2a was first cloned [19],
which we mutated back to the wild type sequence in
order to accurately compare the isoforms. All showed
similar basal levels of transactivation activity (Figure 3,
open boxes). When cotransfected with the adaptors
CITED2 or CITED4, all isoforms gave enhanced activa-
tion of the reporter (P < 0.05) compared to the control
(Figure 3, grey and black boxes). Cotransfection with
p300 or CBP in combination with the different CITED
factors resulted in a further increase in transactivation
activity (P < 0.05) for isoforms 1a, 1b, and 1c (Figure 3).
An exception was isoform 1d, which did not further
transactivate the reporter in the presence of CBP. More-
over, transactivation levels for this isoform were lower
compared with the others. Taken together, these data
suggest that all isoforms (excluding 1d) are able to inter-
act functionally with the adaptors CITED2 or CITED4
with similar efficiency leading to the recruitment of
p300 or CBP.
TFAP2A 1a represses the cyclin D3 promoter via a sumo-
dependent mechanism
Transcriptional activity of the isoforms was further com-
pared using natural promoters from genes known to be
regulated by AP-2a, including those shown to be
repressed by AP-2 factors. We have observed that AP-
2a downregulates cyclin D3 expression, through direct
binding to sites within the proximal promoter (KV
Chan and HC Hurst, unpublished). The activity of AP-
2a isoforms on the cyclin D3 promoter was compared
in HepG2 cells transfected with a reporter comprising
the minimal promoter region (-201/+162) able to drive
cyclin D3 expression. Isoforms 1b and 1c failed to exert
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Figure 3 AP-2a isoforms exert similar transactivation activity when cotransfected with CITED2 or 4 and p300 or CBP. HepG2 cells were
transfected with 0.05 μg pcDNA3-AP-2a, 0.25 μg 3xAP2-Bluc, 0.25 μg phRG-renilla, 0.25 μg pcDNA3-CITED2/4, 1 μg pCI-p300 or pRc/CMV CBP as
indicated. Relative firefly luciferase activity normalised to renilla luciferase activity is shown. Average and standard error from four independent
experiments is reported.
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reporter: expression construct tested (Figure 4). In con-
trast, isoform 1a had a reproducible and significant
repressive effect (Figure 4). Isoform 1d also exerted a
very pronounced inhibitory effect, up to 50% (Figure 4).
The inhibitory effect at a 1:1 ratio was already maximal
for isoforms 1a and 1d, and did not change at higher
ratios for isoforms 1b or 1c (not shown).
A key difference between AP-2a isoform 1a and the
other two isoforms expressed in breast is the presence
of a putative sumoylation site (IKYE) centred at lysine
10 within the sequence encoded by exon 1a. This site is
homologous to the site found in AP-2g which has pre-
viously been demonstrated to be conjugated to SUMO
in vivo thereby reducing AP-2g transactivation activity
[15]. Consequently, we hypothesised that this post-tran-
scriptional modification may also play a role in the
negative regulation of the cyclin D3 promoter by AP-2a
isoform 1a. To test this, a non-sumolylalable mutant of
isoform 1a, K10R, was generated and found to lack
inhibitory activity on the cyclin D3 reporter construct
(Figure 4). AP-2a has previously been demonstrated to
interact with the SUMO E2-conjugating enzyme, UBC9,
in a yeast two-hybrid screen [15], but to confirm that
AP-2a can be sumoylated in vivo, expression constructs
for UBC9 and SUMO-1 (Figure 5a) or SUMO-2 (not
shown) were cotransfected in HepG2 cells together with
the different AP-2a isoforms. This resulted in the
appearance, for isoform 1a only, of a slower migrating
band at approximately 75 kDa, compatible with a
mono-sumoylated form of AP-2a (Figure 5a). Further-
more, mutation of lysine 10 led to a very pronounced
reduction in intensity of this sumoylated band, thus
confirming that lysine 10 is the predominant sumoyla-
tion site in isoform 1a, and explaining why the other
isoforms were not significantly modified.
To confirm that the inhibitory activity of isoform 1a is
dependent on sumoylation, HepG2 cells were cotrans-
fected with the 3xAP2-Bluc reporter and increasing
doses of SUMO-1 or SUMO-2. The transactivation activ-
ity was reduced with SUMO co-transfection, particularly
by SUMO-2, while the transactivation activity of the
K10R mutant or AP-2a 1c was not altered significantly,
suggesting that the most important sumoylation site is
indeed lysine 10 of isoform 1a (Figure 5b). To confirm
that the inhibitory effect exerted by isoform 1a on the
cyclin D3 reporter is due to sumoylation, we co-trans-
fected with either wild-type UBC9 or its sumoylation
defective mutant, C93S [26]. While transfection of wt
UBC9 did not result in further inhibition of cyclin D3
reporter activity, cotransfection of UBC9-C93S partially
reverted the inhibitory activity of isoform 1a (Figure 5c).
In addition, a clear reduction in the level of sumoylated
AP-2a was observed by western blot when the 1a isoform
and UBC9-C93S were co-expressed in the same propor-
tion in HepG2 cells (Figure S3 in Additional File 1).
r
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
u
n
i
t
s
AP-2α 1a AP-2α 1a
K10R
AP-2α 1b AP-2α 1c AP-2α 1d
- 1:0.5 1:1 1:0.5 1:1 1:0.5 1:1 1:0.5 1:1 1:0.5 1:1
cyclin D3 reporter:
AP-2α ratio
∗
∗∗
∗∗ ∗∗
0.0
0.5
1.0
1.5
2.0
Figure 4 AP-2a isoforms differ in their transcriptional repression activity. HepG2 cells were transfected with 0.25 μg/well pGL4.74 (Renilla),
0.4 μg/well cyclin D3 reporter construct, and the indicated ratios of pcDNA3-AP-2a (corresponding to 0.2 and 0.4 μg/well). Results are reported
as relative firefly luciferase activity normalised to renilla luciferase activity. Average and standard error from three independent experiments is
shown.
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Figure 5 AP-2a isoform 1a can be sumoylated leading to decreased transactivation activity. (a) HepG2 cells were transfected with 0.3 μg/
well of the different pcDNA3-AP-2a constructs, without and with 0.1 μg/well pSG5 Ubc9 and 0.6 μg/well pSG5 SUMO1 in a six-well format. 48 h
after transfection, lysates were harvested in RIPA buffer containing IAA and NEM, and analysed by western blot with a pan AP-2a antibody (3B5).
One experiment representative of three is shown. A second, weaker sumoylation site (IKKG) was predicted (using “SUMOplot”) within the C-
terminal half of the protein which could explain the low levels of sumoylation observed for AP-2a K10R and the other isoforms using longer
exposures. (b) HepG2 cells were transfected with 0.05 μg/well of the different pcDNA3-AP-2a constructs, 0.25 μg/well 3xAP2-Bluc, 0.25 μg/well
phRG-renilla, 0.25 μg/well pcDNA3-CITED2, 0.75 μg/well pCI-p300, and 0.25 or 0.5 μg/well pSG-SUMO1/2 as indicated. Relative firefly luciferase
activity normalised to renilla luciferase activity is shown. The average and standard error of three experiments is reported. (c) HepG2 cells were
transfected with 0.2 μg/well pGL4.74 (Renilla), 0.3 μg/well cyclin D3 reporter, 0.15 μg/well pcDNA3-AP-2a isoform 1a, 0.3 μg/well pSG-Ubc9 and
0.15 μg/well pSG-SUMO1. Average and standard error from three independent experiments is represented.
Berlato et al. Breast Cancer Research 2011, 13:R23
http://breast-cancer-research.com/content/13/2/R23
Page 8 of 13TFAP2A isoform 1a is a weaker transactivator of the
ERBB2 promoter
The transactivation activity of the different AP-2a iso-
forms was further tested on the ERBB2 promoter, which
is known to possess two functional AP-2 binding sites,
mapping at -210 and -500 upstream of the transcription
start site, which are required for positive regulation of
ERBB2 by AP-2a in breast tumour lines [22,27]. A repor-
ter carrying ERBB2 promoter sequences (-500/+40) was
co-transfected at different ratios with the AP-2a isoform
expression constructs together with Cited2/p300 (Figure
6). Isoform 1a significantly induced reporter activity at a
1:2 and 1:4 reporter:AP-2a ratio (Figure 6). In contrast,
the transactivation activity of isoforms 1b and 1c was
already significant at a ratio of 1:0.5, and further
increased at higher ratios, reaching a plateau at 1:4. Iso-
form 1d was the most potent transactivator and its activ-
ity increased at higher ratios in an almost linear manner.
Consequently, it appears that isoform 1a is the weakest
transcriptional activator on the ERBB2 promoter, Thus,
when tested in the context of a complex, natural promo-
ter, differences in transactivation activity between the
TFAP2A isoforms are observed which were not evident
when using the artificial reporter construct (Figure 3). To
examine this further, the relative activity of isoforms 1a,
1b and 1c on the ERBB2 promoter was also compared in
the presence of different combinations of the CITED/
p300/CBP cofactors (Figure S4 in Additional File 1). In
each case, isoform 1a was the weakest activator.
TFAP2A isoform 1c expression increases in tamoxifen-
resistant lines and tumours
Since we observed that AP-2a isoforms have differential
transactivation activity on the ERBB2 promoter, we
decided to investigate their expression in a biological
context. ErbB2 overexpression is associated with resis-
tance to the oestrogen receptor (ER) antagonist tamoxi-
fen, since signalling from the receptor can promote
oestrogen independent activation of the ER (reviewed
[28]). We, therefore, investigated whether AP-2a iso-
form levels were altered in tamoxifen resistant (TR)
lines and tumour samples. Given that isoform 1a was
the weakest activator of ERBB2 expression (Figure 6),
we would predict that increased expression of the other
isoforms might be associated with the tamoxifen resis-
tant phenotype. In three independent TR lines, which
were cultivated in the presence of tamoxifen for at least
six months, we observed a pronounced increase in levels
of ErbB2 compared to the wt controls (Figure S5a, b in
Additional File 1). In the same three lines, levels of iso-
form 1c compared to isoform 1a increased significantly,
as measured by quantifying levels in Western blots as
the ratio between the two isoforms (1c:1a; P < 0.05, see
Figure 7a, b).
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Figure 6 AP-2a isoforms exert different levels of transactivation activity at the ERBB2 promoter. HepG2 cells were transfected with 0.12
μg/well p500 ErbB2-luc, 0.02 μg/well renilla hRG, 0.06 μg/well pCI-p300, 0.06 μg/well pcDNA3-CITED2, and indicated ratios (corresponding to a
total of 0.06, 0.12, 0.24 and 0.48 μg/well) of the different pcDNA3-AP-2a constructs. The average and standard error of three independent
experiments is represented.
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Page 9 of 13This finding led us to compare TFAP2A isoform expres-
sion levels in a small series of mRNA samples from TR
tumours. Good quality RNA from frozen samples was
required to detect isoforms levels with sufficient sensitiv-
ity, and this limited the number of samples available. In
these samples, ERBB2 mRNA levels tended to be higher
compared to normal breast samples (Figure S3c in Addi-
tional File 1; P = 0.043). AP-2a isoform 1c levels were also
higher in TR tumours compared to normal breast (Figure
7c, P = 0.038). No significant change was observed for iso-
form 1a or 1b. Moreover, the difference in ratio between
levels of isoform 1c and 1a in the TR tumours compared
with normal breast was also significant (Figure 7d, P =
0.002). This would suggest a selective and differential reg-
ulation of AP-2a isoforms in tamoxifen resistant tumours.
Discussion
A significant proportion of the reports investigating the
biological function of AP-2a are overexpression studies
which analyse exclusively the first isoform (1a) cloned.
The existence of additional TFAP2A transcripts deriving
from alternative first exons has been described in some
mammals, but there has been little attempt to determine
their importance or function. Our in silico analysis con-
firmed that different isoforms of AP-2a occur in
humans, providing at the same time evidence of a strong
conservation throughout vertebrate evolution (Figure 1).
Furthermore, ESTs for isoforms 1a and 1b can also be
found for the paralogous gene AP-2b. In contrast, we
w e r en o ta b l et oi d e n t i f ya l t e r n a t i v e5 ’ variants for AP-
2g, which is the homolog of AP-2a isoform 1a.
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Figure 7 AP-2a isoform expression is differentially regulated in tamoxifen resistant cell lines and breast tumour samples. (a, b): Levels
of AP-2a isoform 1a and 1c were determined by Western blot in a series of wild-type ER+ breast tumour lines and in their tamoxifen-resistant
counterparts. The signal from a number of different non-saturated exposures was quantified with ImageJ and is graphically represented in (b). (c,
d): Normal breast (4) and tumour samples (10) were analysed by real-time PCR for AP-2a isoform expression levels. The relative levels of AP-2a
1c normalised using GAPDH levels (c) and the ratio between AP-2a 1c and 1a (d) are represented. The differences remain statistically significant
even when the outliers are eliminated from the analysis.
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Page 10 of 13Interestingly, AP-2ε, and possibly the more distantly
related AP-2δ, are more similar to isoform 1b (Figure
1d), suggesting this is the most ancient isoform from
which the family originated in vertebrates. Since we
were unable to detect expression of isoform 1d in the
tissues examined, it probably does not represent a true
isoform. However, the remaining AP-2a isoforms are
expressed at significant levels in breast cell lines and tis-
sue (Figure 2) with the AP-2a 1c protein being found at
levels at least comparable to those of the initially identi-
fied isoform 1a, suggesting that its activity in the breast
should be investigated.
Our analysis focused on testing whether differences in
amino-terminal sequence lead to distinct biological
characteristics for the AP-2a isoforms. The N-terminus
of AP-2a encompasses the transactivation domain, and
is not involved either in DNA binding or in protein
dimerisation [1]. Therefore, functional differences are
more likely to be found in transactivation activity,
although the limited difference in sequence might sug-
gest subtle variations. With a synthetic reporter, iso-
forms 1a, 1b and 1c showed similar transactivation
activity indicating a similar ability to interact function-
ally with CITED2 or CITED4 and p300 or CBP. This
agrees with the finding that the domain essential for
interaction with CITED2 lies in the central (common)
region of AP-2a [9]. However, the picture changed
when the transactivation activity of the isoforms was
compared using natural promoters. The cyclin D3 pro-
moter was differentially regulated by the different iso-
forms with AP-2a 1b and 1c having a minimal effect,
whereas isoform 1a exerted a significant inhibitory activ-
ity, similar to the effect exerted by AP-2g (KV Chan and
HC Hurst, unpublished). Lysine 10, which lies within a
putative sumoylation motif, was essential for this inhibi-
tory activity. An interaction between AP-2a and UBC9
has been demonstrated previously [15] and our subse-
quent experiments showed that isoform 1a alone could
be sumoylated in HepG2 cells. However, sumoylation of
endogenous AP-2a in breast lines could not be con-
firmed. When a similar experiment was performed for
AP-2g using MCF7 cells, which express it at high levels,
only a small fraction of the protein was found to be
sumoylated [15], in accord with similar studies on other
sumoylated proteins [29]. By extrapolation, since in
breast lines levels of isoform 1a represent only a propor-
tion of the total AP-2a protein (Figure 2), it is likely
that the fraction of sumoylated isoform 1a falls below
the level detectable using Western blotting or immuno-
precipitation. Co-transfection of SUMO-1 or SUMO-2
with isoform 1a resulted in reduced transactivation
activity, similar to observations made for AP-2g [15].
The finding that for AP-2a only isoform 1a can act as a
repressor strengthens the hypothesis that sumoylation is
necessary for AP-2 transcriptional repression. Moreover,
we have linked for the first time the negative regulatory
effect on the natural cyclin D3 promoter to sumoylation
of AP-2a, since overexpression of mutant Ubc9 reverted
the inhibitory activity of isoform 1a.
On the ERBB2 promoter, isoforms 1b and 1c both
exerted significant transactivation activity at low repor-
ter:expression plasmid ratios (Figure 6), while isoform
1a only achieved a similar level of transactivation activity
when two to four times more expression plasmid was
used, despite very similar expression efficiencies for all
three expression constructs. This was initially explored
using CITED2/p300 cofactors since CITED2 is consid-
ered to be the most biologically relevant cofactor for
TFAP2A due to the similarity in phenotype between the
respective knock-out mice. Moreover, a recent genome-
wide analysis of CBP and p300 binding suggested that
p300 is significantly more associated with AP-2 sites
compared to CBP [30]. However, we have also com-
pared cofactor preferences for the TFAP2A isoforms on
both the synthetic and ERBB2 promoters at a variety of
ratios (Figures 3, 6, S4 and data not shown) and noted
that CITED4 also acts efficiently with isoforms 1b and
1c. However, with all cofactor combinations, isoform 1a
was consistently the weakest transactivator at the nat-
ural ERBB2 promoter. It is significant, therefore, that we
have observed that isoform 1c levels are higher in
tamoxifen resistant breast tumour samples and cell
lines. Although this observation has to be treated with
some caution because of the limited number of samples
available to assay, it suggests that AP-2a isoforms may
have differential roles in tumourigenesis due to varia-
tions in their transactivation activity on key target genes
such as ERBB2.
These data demonstrate that the short sequence of
amino acids encoded by the first exons affects signifi-
cantly the transactivation potential of AP-2a. In particu-
lar isoform 1a may be a weaker transactivator and,
potentially, has a more specialised function as an inhibi-
tor of transcription on AP-2a repressed genes. The lack
of repressor activity shown by isoforms 1b and 1c may
be explained by the absence of the sumoylation motif.
Alternatively, the sequence encoded by these isoforms
may mediate an enhanced activation function that
masks any inhibitory activity. Isoform 1c possesses a
well conserved lysine residue, which is a possible target
for a variety of regulatory post-translational modifica-
tions, including ubiquitination, acetylation and methyla-
tion, which will be the object of further investigations.
Conclusions
The different isoforms of AP-2a possess differential
transactivation and repression activities which are
dependent on the promoter context. AP-2a isoform 1c
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Page 11 of 13is expressed at significant levels in breast cell lines and
tissues, and can be the predominant isoform. These
observations underline the need to determine which iso-
forms are expressed at the protein level in different tis-
sues and tumours, and that the complexity of the
different AP-2a isoforms has to be considered when
conducting promoter studies on AP-2 target genes.
Moreover, further studies are needed to analyse AP-2a
isoform 1c function in the breast and during tumouri-
genesis. Indeed, differences between the isoforms may
help to reconcile contradictory effects reported for AP-
2a, in particular in breast tumour studies, and also may
explain the partially overlapping yet distinct roles
observed for AP-2a, b and g during development.
Additional material
Additional file 1: Supplementary Figures S1 to S5. A PDF file with
each of the supplementary figures referred to in the text, together with
an explanatory legend.
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